Welcome to our dedicated page for Kalvista Pharm news (Ticker: KALV), a resource for investors and traders seeking the latest updates and insights on Kalvista Pharm stock.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) generates frequent news flow around its work in hereditary angioedema (HAE) and the commercialization of EKTERLY (sebetralstat). Company press releases highlight regulatory approvals, commercial launches, clinical data presentations and financial updates tied to this first and only oral on-demand treatment for acute HAE attacks in people 12 years of age and older.
News items cover major milestones such as FDA approval of EKTERLY in the United States, subsequent approvals in the European Union, United Kingdom, Switzerland, Australia, Singapore and Japan, and the initiation of commercial launches in the U.S. and Germany. KalVista also reports on licensing and commercialization agreements with partners like Kaken Pharmaceutical in Japan, Pendopharm in Canada and Multicare Pharmaceuticals in Latin America, which expand EKTERLY’s reach into additional markets.
Investors and clinicians following KALV can track updates on net product revenue from EKTERLY, patient start forms, prescriber activation and refill trends, as well as financing events such as the issuance of convertible senior notes. The company regularly announces new clinical and real‑world data from the KONFIDENT, KONFIDENT‑S and KONFIDENT‑KID studies, including patient satisfaction, pediatric interim results and European experience with sebetralstat, often presented at meetings such as the American College of Allergy, Asthma & Immunology Annual Scientific Meeting and the German Allergy Congress.
Additional KalVista news includes corporate governance developments, board and executive appointments, inducement equity grants and participation in healthcare investor conferences. This news page allows readers to follow how KalVista advances EKTERLY globally, engages with the HAE community and reports on its operational and financial progress over time.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced its participation at the virtual SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET. A live webcast of the presentation will be available on the company's website, with an audio archive for 30 days post-event. KalVista focuses on developing oral, small molecule protease inhibitors for conditions such as hereditary angioedema (HAE) and diabetic macular edema (DME). The company is actively conducting the Phase 3 KONFIDENT trial for its oral therapy, sebetralstat, targeting HAE attacks and has a pipeline that includes a novel plasma kallikrein inhibitor for DME.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options to two new employees, allowing them to purchase a total of 14,000 shares of common stock at an exercise price of $7.64 each, equal to the stock's closing price on the grant date, February 1, 2023. The options will vest over a four-year period, with one-fourth vesting on the one-year anniversary and the remainder in monthly installments, contingent on continued employment. This move follows Nasdaq Listing Rule 5635(c)(4) and aligns with KalVista's commitment to attracting talent in the pharmaceutical sector, particularly in developing therapies for hereditary angioedema and diabetic macular edema.
KalVista Pharmaceuticals has promoted Ben Palleiko to President, expanding his role to lead business and commercial growth following a $58 million financing in December 2022. This financing, led by notable investors, enhances the company’s financial position, providing access to over $190 million for the ongoing Phase 3 KONFIDENT trial for sebetralstat, an oral treatment for hereditary angioedema (HAE). The company anticipates filing a New Drug Application by mid-2024, with data expected in H2 2023.
KalVista Pharmaceuticals has announced a registered direct offering of 9.484 million shares at $6.00 per share and 182,470 prefunded warrants at $5.999, totaling approximately $58 million in gross proceeds. The offering is set to close on December 28, 2022, pending customary conditions. Proceeds will fund clinical trials, commercial sales development, research, and working capital, enabling operations funding into 2025. The shares are offered under an effective shelf registration statement with the SEC, enhancing liquidity for future projects and developments.
KalVista Pharmaceuticals (NASDAQ: KALV) has completed its Phase 1 clinical trial for an orally disintegrating tablet formulation of sebetralstat, with promising results published in the Journal of Medicinal Chemistry and Xenobiotica. Despite terminating the Phase 2 KOMPLETE trial for KVD824 due to safety concerns, the company remains focused on advancing its Phase 3 KONFIDENT trial for sebetralstat, expecting data in H2 2023. Financially, KALV recorded no revenue for Q2, with a net loss of $22.3 million. Cash on hand is $122.3 million, down from $166.2 million, primarily due to operating expenses.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced the granting of inducement stock options for 2,000 shares to a newly-hired employee, effective December 1, 2022. The options have an exercise price of $5.34, matching the closing stock price on the grant date. Vesting occurs in stages, with a quarter vesting after one year and the remainder in monthly installments over three years. KalVista focuses on developing innovative therapies for conditions like hereditary angioedema and diabetic macular edema, with ongoing clinical trials for sebetralstat and KVD001.
KalVista Pharmaceuticals (NASDAQ: KALV) presented two impactful posters at the 2022 American College of Allergy, Asthma & Immunology meeting, revealing the significant effects of hereditary angioedema (HAE) attacks on patients' mental health and daily activities. Over half of HAE patients reported limitations in functions due to the condition. The second poster highlighted the treatment burden related to on-demand parenteral therapies, noting common adverse drug reactions. CEO Andrew Crockett emphasized the need for less traumatic treatment options, leading to KalVista’s focus on developing oral therapies for HAE.
KalVista Pharmaceuticals, Inc. (NASDAQ: KALV) announced participation in investor conferences, including the Stifel 2022 Healthcare Conference on November 15, 2022, and the Jefferies London Healthcare Conference on November 17, 2022. Live webcasts of both presentations will be accessible on KalVista's website, with an audio archive available for 30 days post-event. KalVista focuses on developing oral, small molecule protease inhibitors for conditions like hereditary angioedema (HAE) and diabetic macular edema (DME), with ongoing clinical trials for its lead candidate, sebetralstat.
KalVista Pharmaceuticals (NASDAQ: KALV) announced the granting of inducement stock options to a newly hired employee. A total of 2,000 shares were issued at an exercise price of $5.10 per share, equivalent to the closing price on November 1, 2022. The options will vest over four years, with 25% vesting after one year and the remainder in monthly increments. This move aligns with Nasdaq Listing Rule 5635(c)(4) and aims to incentivize the new employee's ongoing contribution to the company.
KalVista Pharmaceuticals (NASDAQ: KALV) announced positive Phase 1 results for an orally disintegrating tablet (ODT) formulation of its lead compound, sebetralstat, aimed at treating hereditary angioedema (HAE). The trial involved 36 healthy adult volunteers and indicated a similar pharmacokinetic profile between the ODT and the existing film-coated tablets. The company plans to develop the ODT further and aims for its availability post-launch of sebetralstat. Data from the ongoing Phase 3 KONFIDENT trial is expected in H2 2023, supporting a planned NDA filing in H1 2024.